Comment on Christiaens et al. Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study. Diabetes Care 2025;48:61-66 [0.03%]
克里斯坦斯等人的糖尿病过度治疗和老年2型糖尿病患者在接受胰岛素治疗时的低血糖：HYPOAGE队列研究的新见解《糖尿病护理》2025;48:61-66
Ching-Yang Cheng,Chien-Ning Huang,Yi-Sun Yang et al.
Ching-Yang Cheng et al.
Type 1 Diabetes TrialNet: Leading the Charge in Disease Prediction, Prevention, and Immunotherapeutic Mechanistic Understanding [0.03%]
糖尿病临床试验网（TrialNet）：引领疾病预测、预防及免疫治疗机制理解研究
Laura M Jacobsen,Jamie L Felton,Brandon M Nathan et al.
Laura M Jacobsen et al.
Established by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in 2001, Type 1 Diabetes TrialNet (TrialNet) is an international consortium of clinical research centers that studies the development of type 1 diab...
Youth-Onset Type 2 Diabetes: What We've Learned From Key Youth-Onset Type 2 Diabetes Studies, What We Still Don't Know, and Why It Is Important [0.03%]
2型糖尿病的发病机理：来自关键性的青少年2型糖尿病研究的启示、尚未知悉的问题及其重要意义
Kristen J Nadeau,Elizabeth J Mayer-Davis,Rose Gubitosi-Klug et al.
Kristen J Nadeau et al.
In this review, we describe the epidemiology, pathophysiology, pediatric-specific treatment response data, morbidity, and mortality of youth-onset type 2 diabetes. In recognition of the National Institute of Diabetes and Digestive and Kidne...
The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact [0.03%]
糖尿病预防计划及其结果研究：NIDDK在2型糖尿病预防及其公共卫生影响方面的探索之旅
Jill P Crandall,Dana Dabelea,William C Knowler et al.
Jill P Crandall et al.
The current-day epidemic of type 2 diabetes, largely driven by increased adiposity and reduced physical activity in the setting of genetic susceptibility, is a major public health challenge. The National Institute of Diabetes and Digestive ...
William T Cefalu,Rebecca J Cerio,Corinne M Silva et al.
William T Cefalu et al.
Unfolding the Mystery of Autoimmunity: The Environmental Determinants of Diabetes in the Young (TEDDY) Study [0.03%]
解开自身免疫之谜：“环境决定因素和糖尿病青少年研究（TEDDY）”
Marian Rewers,Daniel Agardh,Suzanne Bennett Johnson et al.
Marian Rewers et al.
In 2025, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health celebrates 75 years of leadership in diabetes research. The NIDDK serves people of the U.S. affected by or at risk fo...
The NIDDK Takes on the Complications of Type 1 Diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study [0.03%]
糖尿病控制和并发症试验/糖尿病干预与并发症流行病学研究（DCCT/EDIC）项目中的美国国立糖尿病、消化疾病和肾脏疾病研究所
Barbara H Braffett,Ionut Bebu,Gayle M Lorenzi et al.
Barbara H Braffett et al.
In the Diabetes Control and Complications Trial (DCCT) (1983-1993), intensive therapy aimed at near-normal glycemia was compared with conventional therapy in 1,441 adolescent and adult participants with type 1 diabetes (T1D) over a mean fol...
NIDDK at 75 Years of Age: Great Triumphs but Concerns for Its Longevity [0.03%]
NIH糖尿病、消化疾病和肾脏病研究所成立75周年：辉煌成绩与未来展望
Steven E Kahn,Cheryl A M Anderson,John B Buse et al.
Steven E Kahn et al.
Editorial
Diabetes care. 2025 Apr 24:dci250033. DOI:10.2337/dci25-0033 2025
Capillary Ketone Level and Future Ketoacidosis Risk in Patients With Type 1 Diabetes Using Sodium-Glucose Cotransporter Inhibitors [0.03%]
使用钠-葡萄糖共转运蛋白抑制剂的1型糖尿病患者的毛细血管酮体水平及其对未来糖尿病酮症酸中毒风险的影响
Priya Bapat,Sharon Dhaliwal,Cimon Song et al.
Priya Bapat et al.
Objective: We aimed to determine if routine capillary blood ketone testing on well days predicts future diabetic ketoacidosis (DKA) in type 1 diabetes (T1D) using sodium-glucose cotransporter inhibitors (SGLTi). ...
Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial [0.03%]
体重增加与GRADE随机临床试验中2型糖尿病患者血糖恶化和心血管及肾脏结局恶化独立于糖尿病药物有关
Deborah J Wexler,W Timothy Garvey,Alokananda Ghosh et al.
Deborah J Wexler et al.
Objective: Weight gain with glucose-lowering medications may interfere with effective type 2 diabetes (T2D) management. We evaluated weight change and the effect of weight gain on outcomes over 5 years on four diabetes me...